Article Per Year (5 Year)
p-Index From 2019 - 2024
0.702
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana
Jovita Jutamulia
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System: Oral Presentation - Observational Study - General practitioner Dewa Ayu Anggi Paramitha; Ajeng Kartika Ayu Putri; Seruni Hanna Ardhia; Jovita Jutamulia
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/v8vmp587

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System Dewa Ayu Anggi Paramitha; Ajeng Kartika Ayu Putri; Seruni Hanna Ardhia; Jovita Jutamulia
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/zh73sh38

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Oral Vitamins for Lowering the Risk of Cataracts: Is It Needed? Poster Presentation - Observational Study - General practitioner gabriella Hafidha Badruddin; Stella Nathania; Nadya Safira; Jovita Jutamulia; Muthia Despi Utami
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/dqzwae69

Abstract

Introduction & Objectives : Cataracts are a common age-related ocular disorder leading to blindness. As the role of oral vitamins in the prevention of cataracts remains controversial, various studies have investigated the potential association between oral vitamin supplementation and risk of cataracts. This review aims to find association between oral vitamins and the risk of cataracts. Methods : A thorough literature research was conducted on online databases (PubMed, ProQuest, and Cochrane) and hand-searching. This review incorporates human studies in the past decade (2013-2023), conducted concerning the correlation between various kinds of oral vitamins and cataracts. All studies shall be published in English and be available in full-text journals. Results : The majority of studies indicated that vitamin C, vitamin E, and multivitamin supplementations were associated with lower risks of cataract incidence. Two articles had similar relative risks (RR) for vitamin C (RR = 0.80-0.81), one article had RR of 0.90 for vitamin E, while two others had RR of 0.66 and hazard risk (HR) of 0.91 for multivitamin. However, one cohort stated otherwise as both vitamin C and vitamin E increased the risk of developing cataracts (HR = 1.21 and 1.59, respectively), while multivitamin had no association (HR = 0.96). Conclusion : Oral multivitamin, vitamin C, and E have a significant association with cataracts. Further research is needed to specify the efficacy of each vitamin.
Exploring the Impact of Low-Concentration Atropine Eye Drops on the Progression of Myopia: A Systematic Review: Oral Presentation - Observational Study - General practitioner Stella Nathania; Gabriella Hafidha Badruddin; Jovita Jutamulia
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/e6r6ya10

Abstract

Abstract Introduction & Objectives : Low-concentration atropine eye drops have emerged as a promising therapy for the management of myopia. However, the effectiveness of atropine for myopia has not been widely studied. This paper aims to analyze the efficacy of low-concentration atropine eye drops for progression of myopia. Methods : A comprehensive literature search was performed on 3 online databases: PubMed, Cochrane, and ProQuest. We used 'Low-concentration atropine eye drops’, ‘Atropine’, ‘Eye Drops’, ‘Myopia’, and their MeSH terms as keywords. All studies included in analysis were available in English and full text format. We analyzed children myopia progression rates from all studies. We used Rayyan, an online-based tool, to conduct the screening process. Results : Three randomized control trials (RCTs), two cohort studies, and three case report studies with a total of 1389 participants were analyzed. Most studies were done in Asia, except one RCT in Australia. The participants range from 4-12 years old. Atropine eye drops concentrations that had been used were 0,01%, 0,025%, 0,05%, 0,1%, 0,125%, and 0,2%. All studies showed slower progression rate of myopia compared to the control group (-0,31 D vs -0,90 D; -0,05 D vs -1,05 D; -0,27 D vs -0,81 D; -0,28 D vs -0,54 D; -0,18 D vs -0,45 D;−0.31 D vs −0.76 D; -0.91 vs -1.00 D; -0,38D vs -0,55 D) with P < 0,05, except one study P = 0,94. Conclusion : Low-concentration atropine eye drops have shown promising effects in slowing progression of myopia. However, further research is needed, particularly in non-Asian countries.
Co-Authors Ajeng Kartika Ayu Putri Dewa Ayu Anggi Paramitha gabriella Hafidha Badruddin Muthia Despi Utami Nadya Safira Seruni Hanna Ardhia Stella Nathania